Genetic studies have demonstrated that ATC originates from pre-existing papillary thyroid cancer involving BRAF or RAS mutations that have subsequently evolved toward ATC by acquiring additional genetic aberrations, particularly in TP53, PIK3CA, and TERT promoters. The gene discussed is TP53; the disease is thyroid gland papillary carcinoma.